Still expensive, but a solution is within reach
08/10/19 -"According the press, an out of court settlement for all Glyphosat-based cases seems now to be on Mr Baumann's agenda. Having lost the three original cases in the US, the idea of settling all of them ..."
Pages
70
Language
English
Published on
08/10/19
You may also be interested by these reports :
29/01/26
Roche finished the year on a strong note, backed by healthy performances across key focus areas. Even the 2026 guidance was encouraging. The ...
28/01/26
Lonza’s full-year 2025 CDMO performance surpassed management’s guidance. Top-line growth was driven by strong double-digit increases in Integrated ...
28/01/26
2025 was a year of US tariff threats and drug pricing pressure on the pharma industry, and for AstraZeneca (REDUCE; UK), it started under the cloud ...
27/01/26
Critical USA size increase with value-accretive capacity acquisition